» Articles » PMID: 35884428

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 27
PMID 35884428
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillance in immune-refractory tumors. An option to elicit antitumor immunity against cancer consists of using approved and marketed drugs known for their capacity to modulate the expression and functioning of the PD-1/PD-L1 checkpoint. Here, we have reviewed several types of drugs known to alter the checkpoint, either directly via the blockade of PD-L1 or indirectly via an action on upstream effectors (such as STAT3) to suppress PD-L1 transcription or to induce its proteasomal degradation. Specifically, the repositioning of the approved drugs liothyronine, azelnidipine (and related dihydropyridine calcium channel blockers), niclosamide, albendazole/flubendazole, and a few other modulators of the PD-1/PD-L1 checkpoint (repaglinide, pimozide, fenofibrate, lonazolac, propranolol) is presented. Their capacity to bind to PD-L1 or to repress its expression and function offer novel perspectives for combination with PD-1 targeted biotherapeutics. These known and affordable drugs could be useful to improve the therapy of cancer.

Citing Articles

Application of Nanotechnology and Phytochemicals in Anticancer Therapy.

Kim J, Dareowolabi B, Thiruvengadam R, Moon E Pharmaceutics. 2024; 16(9).

PMID: 39339205 PMC: 11435124. DOI: 10.3390/pharmaceutics16091169.


The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer.

Mandal S, Yadav P, Sheth R Int J Mol Sci. 2024; 25(11).

PMID: 38892423 PMC: 11172507. DOI: 10.3390/ijms25116237.


Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway.

Xia W, Zheng X, Liu W, Huang Y, Wen C, Zhou H Cancer Gene Ther. 2024; 31(5):778-789.

PMID: 38480975 DOI: 10.1038/s41417-024-00760-0.


Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment.

Karnik I, Her Z, Neo S, Liu W, Chen Q Pharmaceutics. 2023; 15(6).

PMID: 37376049 PMC: 10305679. DOI: 10.3390/pharmaceutics15061600.

References
1.
Peters J, Booth A, Peters R . Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015; 6(4):160-9. PMC: 4480546. DOI: 10.1177/2040622315582353. View

2.
Mohapatra P, Srivastava R, Varshney K, Babu S . Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach. Anticancer Agents Med Chem. 2021; 22(10):1984-2001. DOI: 10.2174/1871520621666210805125426. View

3.
Yeh L, Lin C, Lu K, Hsieh Y, Yeh C, Yang S . Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway. Int J Mol Sci. 2022; 23(1). PMC: 8745393. DOI: 10.3390/ijms23010484. View

4.
Ikeda K, Saito T, Tojo K . Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011; 224(4):263-71. DOI: 10.1620/tjem.224.263. View

5.
Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A . Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):434-454. PMC: 6528778. DOI: 10.1016/j.bbcan.2019.04.005. View